Antibiotics with promise — a lifeline India awaits
In the relentless battle against highly drug resistant infections, a team of doctors recently witnessed a glimmer of hope amid the challenges they faced. An Indian innovation was made to deal with drug resistant pathogens.
- An Indian Innovation: A promising antibiotic, cefepime/zidebactam, developed by Indian researchers, combines two active components to combat drug-resistant gram-negative pathogens, including Pseudomonas aeruginosa.
- Made by Japan: Ce?derocol, a licenced antibiotic in several countries, developed by a Japanese company, has demonstrated excellent e?cacy against drug resistant infections.
- Emergency Use Authorisation (EUA): This extraordinary case underscores the urgent importance of granting EUA for antibiotics currently in phase 3 trials or licensed from other countries.
Challenges faced in dealing with drug resistant infections
- Limited effective choices- Doctors must navigate through a shrinking arsenal of e?ective antibiotics, leaving them with limited choices.
- Side effects- Often resorting to suboptimal treatments that may have signi?cant side e?ects or o?er little hope of a cure.
- Pressure build up- The constant race against time, trying to stay one step ahead of the mutating bacteria, adds to the immense pressure and helplessness experienced by doctors on the front lines.
- Commitment- India, a nation that has demonstrated remarkable progress in granting EUA for COVID19 vaccines must show the same commitment in this field.
- Thoroughly Evaluated- We need antibiotics that have been thoroughly evaluated or proven to be e?ective are essential in the battle against superbugs.
- Doctor’s approval made mandatory- A collective decision by a team of experienced doctors, including infectious diseases experts should be made mandatory before utilizing these antibiotics.